A novel method for the analysis of the androgen receptor

Current Urology Reports

Volumn 3, Issue 1, 2002, Pages 67-74

  Gaston, Kris E ^a   Harris Ford, O ^a   Singh, Swaroop ^a   Gregory, Christopher W ^a   Weyel, Donald E ^a   Smith, Gary J ^a   Mohler, James L ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Androgen; Androgen Receptor; Androgen Receptor Expression; Benign Prostatic Hyperplasia; Prostate Cancer

Indexed keywords

ANDROGEN RECEPTOR;

ANIMAL; CHEMISTRY; COLOR; HUMAN; IMAGE PROCESSING; IMMUNOHISTOCHEMISTRY; MALE; PROSTATE TUMOR; REVIEW; VIDEORECORDING;

ANIMALS; COLOR; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; MALE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; VIDEO RECORDING;

EID: 0036481432     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-002-0013-8     Document Type: Article

References (44)

1. Huggins C, Hodge CV: The effects of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941, 1:942.
2. Brolin J, Ekman P: Microassays for androgen and progesterone receptor quantitation as compared with standard saturation analysis in human prostatic tissues. Urol Res 1991, 19:333–336. DOI: 10.1007/BF00310145
3. Tsai MJ, O’Malley BW: Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Ann Rev Biochemistry 1994, 63:451–486. DOI: 10.1146/annurev.bi.63.070194.002315
4. Fang S, Anderson KM, Liao S: Receptor proteins for androgens: on the role of specific proteins in selective retention of 17-beta-hydroxy-5-alpha-androstan-3-one by rat ventral prostate in vivo and in vitro. J Biol Chem 1969, 244:6584–6595.
5. Chang C, Kokontis J, Liao S: Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science 1988, 240:324–326. DOI: 10.1126/science.3353726
6. Lubahn DB, Joseph DR, Sullivan PM, et al.: Cloning of human androgen receptor complementary DNA and localization to the X chromosome. Science 1988, 240:327–330. DOI: 10.1126/science.3353727
7. Schoenberg MP, Hakimi JM, Wang S, et al.: Microsatellite mutation (CAG24-18) in the androgen receptor gene in human prostate cancer. Biochem Biophys Res Commun 1994, 198:74–80. DOI: 10.1006/bbrc.1994.1011
8. Chamberlain NL, Driver ED, Miesfeld RL: The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res 1994, 22:3181–3186. DOI: 10.1093/nar/22.15.3181
9. Irvine RA, Yu MC, Ross RK, Coetzee GA: The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res 1995, 55:1937–1940.
10. Gerber HP, Seipel K, Georgiev O, et al.: Transcriptional activation modulated by homopolymeric glutamine and proline stretches. Science 1994, 263:808–811. DOI: 10.1126/science.8303297
11. Choong CS, Kemppainen JA, Zhou A, Wilson EM: Reduced androgen receptor gene expression with first exon CAG repeat expansion. Mol Endocrinol 1996, 10:1527–1535. DOI: 10.1210/me.10.12.1527
12. Murtha P, Tindall DJ, Young YF: Androgen induction of a human prostate-specific kallikrein, hKLK2: characterization of an androgen response element in the 5′ promoter region of the gene. Biochemistry 1993, 32:6459–6464. DOI: 10.1021/bi00076a020
13. Langley E, Shou ZX, Wilson EM: Evidence for an anti-parallel orientation of the ligand human androgen receptor dimer. J Biol Chem 1995, 270:29983–29990. DOI: 10.1074/jbc.270.10.5251
14. Veldscholte J, Berrevoets CA, Brinkman AO, et al.: Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation. Biochemistry 1992, 31:2393–2399. DOI: 10.1021/bi00123a026
15. Kallio PJ, Janne OA, Palvimo JJ: Agonists, but not antagonists, alter the conformation of the hormone-binding domain of the androgen receptor. Endocrinology 1994, 134:998–1001. DOI: 10.1210/en.134.2.998
16. Walsh PC, Madden JD, Harrod MJ, et al.: Familial incomplete male pseudohermaphroditism, type 2. Decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias. N Engl J Med 1974, 291:944–949. DOI: 10.1056/NEJM197410312911806
17. Ogryzko VV, Kotani T, Zhang X, et al.: Histone-like TAFs with the PCAF histone acetylase complex. Cell 1998, 94:35–44. Elucidation of coactivator mechanisms of action. DOI: 10.1016/S0092-8674(00)81219-2
18. Kang H, Yeh S, Fujimoto N: Cloning and characterization of human prostate coactivator ARA54, a novel protein that associates with androgen receptor. J Biol Chem 1999, 274:8570–8576. DOI: 10.1074/jbc.274.13.8570
19. Fujimoto N, Yeh S, Kang H: Cloning and characterization of androgen receptor coactivator, ARA55, in human prostate. J Biol Chem 1999, 274:8316–8321. DOI: 10.1074/jbc.274.12.8316
20. Oñate SA, Tsai SY, Tsai M: Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 1995, 270:1354–1357. DOI: 10.1126/science.270.5240.1354
21. Li H, Gomes PJ, Chen JD: RAC3, a steroid/nuclear receptorassociated coactivator that is related to SRC-1 and TIF2. Proc Natl Acad Sci U S A 1997, 94:8479–8484. DOI: 10.1073/pnas.94.16.8479
22. Vogel JJ, Heine MJS, Zechel C: TIF2, a 160-kDa transcription mediator for the ligand-dependent activation function AF-2 of nuclear receptors. EMBO J 1996, 15:3667–3675.
23. Miyamoto H, Yeh S, Wilding G, Chang C: Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA 70, in human prostate cancer DU145 cells. Proc Natl Acad Sci U S A 1998, 95:7379–7384. Mechanisms showing how androgen receptor activation may occur in the presence of low ligand levels if sufficient amounts of coactivators are present. DOI: 10.1073/pnas.95.13.7379
24. Coons AH, Creech HJ, Jones RN: Immunological properties of an antibody containing a fluorescent group. Proc Soc Exp Biol Med 1941, 47:200–202.
25. Köhler G, Milstein C: Continuous cultures of fused cells producing antibodies of predefined specificity. Nature 1975, 256:495–497. DOI: 10.1038/256495a0
26. Sar M: Application of avidin-biotin complex technique to the localization of estradiol receptor in target tissues using monoclonal antibodies. In Techniques in Immunocytochemistry. Edited by Bullock GR, Petrusz P. New York: Academic Press; 1985:43–54.
27. Tan JA, Joseph DR, Quarmby VE, et al.: The rat androgen receptor: primary structure, autoregulation of its messenger RNA and immunocytochemical localization of the androgen receptor protein. Mol Endocrinol 1988, 2:1276–1285.
28. Quarmby VE, Kemppaininen JA, Sar M, et al.: Expression of recombinant androgen receptor in cultured mammalian cells. Mol Endocrinol 1990, 4:1399–1407. DOI: 10.1210/mend-4-9-1399
29. Benno RH, Tucker LW, Joh TH, Reis DJ: Quantitative immunocytochemistry of tyrosine hydroxylase in rat brain. I. Development of a computer assisted method using the peroxidase-antiperoxidase technique. Brain Res 1982, 246:225–236. DOI: 10.1016/0006-8993(82)91170-2
30. Wainstein MA, He F, Robinson D, et al.: CWR22: androgendependent xenograft model derived from a primary human prostatic carcinoma. Cancer Res 1994, 54:6049–6052.
31. Kononen J, Bubendorf L, Kallioniemi A, et al.: Tissue microarrays for high-throughput molecule profiling of tumor specimens. Nature Med 1998, 7:767–768.
32. Kim D, Gregory CW, Smith GJ, Mohler JL: Immunohistochemical quantitation of androgen receptor expression using color video image analysis. Cytometry 1999, 35:2–10. Article describes using color video image analysis for quantitation of the androgen receptor. DOI: 10.1002/(SICI)1097-0320(19990101)35:1<2::AID-CYTO2>3.0.CO;2-Y
33. Kim D, Charlton JD, Coggins JM, Mohler JL: Semiautomated nuclear shape analysis of prostatic carcinoma and benign prostatic hyperplasia. Anal Quant Cytol Histol 1994, 16:400–414.
34. Gonzalez RC, Woods RE: Color image processing. In Digital Image Processing. Edited by Gonzalez RC. Reading, MA: Addison-Wesley; 1992:229–237.
35. Mixze RR, Holdefer RN, Nabors LB: Quantitative immunohistochemistry using an image analyzer. I. Hardware evaluation, image processing, and data analysis. J Neurosci Methods 1988, 26:1–24. DOI: 10.1016/0165-0270(88)90125-2
36. Otsu N: A threshold selection method for gray-level histograms. Trans Systems Man Cybernetics 1979, 9:62–66. DOI: 10.1109/TSMC.1979.4310076
37. Sadi MV, Barrack ER: Image analysis of androgen receptor immunostaining in metastatic prostate cancer. Heterogeneity as a predictor of response to hormonal therapy. Cancer 1993, 71:2574–2580. DOI: 10.1002/1097-0142(19930415)71:8<2574::AID-CNCR2820710823>3.0.CO;2-1
38. Tilley WD, Lim-Tio SS, Horsfall DJ, et al.: Detection of discrete androgen receptor epitopes in prostate cancer by immunostaining: measurement by color video analysis. Cancer Res 1994, 54:4096–4102.
39. Prins GS, Sklarew RJ, Pertschuk LP: Image analysis of androgen receptor immunostaining in prostate cancer accurately predicts response to hormonal therapy. J Urol 1998, 159:641–649. Article describes how patterns of immunostaining may be correlated to clinical conditions and outcomes. DOI: 10.1016/S0022-5347(01)63692-9
40. Magi-Galluzzi C, Xu X, Hlatky L, et al.: Heterogeneity of androgen receptor content in advanced prostate cancer. Mod Pathol 1997, 10:839–845.
41. Kim D, Gregory CW, French FS, et al.: Androgen receptor expression and cellular proliferation during transition from androgen-dependent to recurrent growth after castration in the CWR22 prostate cancer xenograft. Am J Pathol 2001, in press.
42. Hobisch A, Culig Z, Radmayr C, et al.: Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res 1995, 55:3068–3072.
43. Prins GS, Birch L, Greene GL: Androgen receptor localization in different cell types of the adult rat prostate. Endocrinology 1991, 129:3187–3199. DOI: 10.1210/endo-129-6-3187
44. Zegers ND, Claassen E, Neelen C, et al.: Epitope prediction and confirmation for the human androgen receptor: generation of monoclonal antibodies for multi-assay performance following the synthetic peptide strategy. Biochim Biophys Atca 1991, 1:23–32.